ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Honokiol attenuates neuroinflammation and enhances remyelination in mouse models of multiple sclerosis through PPARγ-mediated ERK/AKT signalling.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is characterized by inflammatory demyelination and insufficient myelin repair, which together drive progressive neurological impairment. While existing immunomodulatory treatments have demonstrated efficacy in reducing acute relapse frequency, they fail to address the critical deficits in oligodendrocyte precursor cell (OPC) differentiation and subsequent remyelination, leaving patients with irreversible neurological disability. This highlights the pressing necessity for pharmacological interventions that can simultaneously mitigate neuroinflammation and stimulate endogenous myelin regeneration. In the present work, we evaluated the therapeutic potential of honokiol, a naturally occurring bioactive polyphenol derived from Magnolia officinalis, using both experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination paradigm. Our results demonstrate that honokiol improved myelin restoration and exerted potent anti-inflammatory effects by suppressing glial activation, modulating inflammatory cytokine profiles, and restoring lipid homeostasis. Transcriptomic analysis indicated a global downregulation of immune-related pathways, and significant upregulation of signalling cascades critically involved in myelination and oligodendrocyte maturation. Molecular dynamics simulations revealed that honokiol stably bound to cannabinoid receptors and peroxisome proliferator-activated receptor gamma (PPARγ) receptor via energetically favourable interactions. In primary OPC cultures, honokiol directly facilitated the differentiation of OPC into mature oligodendrocytes. Pharmacological blockade of PPARγ eliminated both honokiol-induced OPC maturation and subsequent activation of the extracellular signal-regulated kinase/protein kinase B (ERK/AKT) signalling axis. Taken together, these findings indicate that honokiol attenuates neuroinflammation and may facilitate myelin repair through both immunomodulatory actions and direct effects on oligodendrocyte lineage cells, supporting its potential as a disease-modifying strategy for demyelinating disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.